Oral Mucositis - Pipeline Analysis Demonstrates Novel 10+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | Key Players Name: Clevexel Pharma SA, Connext Co Ltd, Destiny Pharma

As per Global Insight services' assessment, about 10+ prominent pharma and biotech giants are working on 10+ drugs in the Oral Mucositis - pipeline landscape globally. Oral Mucositis Pipeline Insight, 2023" report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.

Oral Mucositis also called as stomatitis is an acute inflammation of the mucous membranes of mouth/oral cavity following the systemic cancer therapy and/or radiation therapy.

The most common cause of Oral Mucositis is cancer treatments. The frequent treatments of chemotherapy, radiation of the head, chest, or neck, bone marrow and stem cell transplants can cause mucositis.

Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies: https://www.globalinsightservices.com/request-sample/GIS31248

Symptoms include dry mouth, shiny, swollen, or red gums, mouth pain, painful mouth sores, infection, blood in the mouth, pain or a mild burning sensation while eating, difficulty in swallowing or talking.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Oral Mucositis treatment such as SGX942, Avasopasem, EC-18 and others. Key players involved in the development of therapies to treat Oral Mucositis are Soligenix, Galera Therapeutics, Enzychem Lifesciences Corp, and others. One drug is under Pre-Registration, one drug is under Phase III and four drugs are in Phase II clinical trials and some other drugs are under Phase I, IND/CTA filed, preclinical and discovery stages of development.

Read more about Oral Mucositis Drug Pipeline here: https://www.globalinsightservices.com/reports/oral-mucositis-drug-pipeline-landscape/

Report Highlights

Global Insight Service's, Oral Mucositis - Drug Pipeline Landscape, 2022 report provides an overview of the Oral Mucositis pipeline drugs. This report covers detailed insights on Oral Mucositis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Oral Mucositis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Key Players :

• Allander Biotechnologies LLC
• Clevexel Pharma SA
• Connext Co Ltd
• Destiny Pharma
• Enzychem Lifesciences Corporation
• Galera Therapeutics, Inc
• Lakewood-Amedex, Inc
• Matrix Biomed, Inc.
• MitoImmune Therapeutics
• Monopar Therapeutics

Purchase your copy now: https://www.globalinsightservices.com/checkout/single_user/GIS31248

Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.